Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche And Curadev Sign IDO1/TDO Pact
by Lisa M. Jarvis
April 27, 2015
| A version of this story appeared in
Volume 93, Issue 17
Roche is paying Curadev Pharma $25 million up front as part of a research pact to develop small molecules that block IDO1 and TDO, enzymes that help cancer cells hide from the immune system. New Delhi-based Curadev also gets research funding and could reap up to $530 million in milestones if IDO1/TDO inhibitors reach the market. Last October, Roche’s Genentech unit paid NewLink Genetics $150 million for access to its IDO1 inhibitor NLG919.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter